C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.070
-0.100 (-3.15%)
May 12, 2026, 9:31 AM EDT - Market open

C4 Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2022FY 2021FY 2020
Period Ending
May '26 Dec '25 Dec '24 Dec '22 Dec '21 Dec '20
338185254---
Market Cap Growth
209.41%-27.20%----
Enterprise Value
112.16-9.8269.33000
Last Close Price
3.071.913.605.9032.2033.13
PE Ratio
--1.50-2.37-2.25-17.69-5.68
PS Ratio
9.725.157.15---
PB Ratio
1.200.721.18---
P/TBV Ratio
1.270.621.161.003.811.34
P/FCF Ratio
--1.86-3.89---
P/OCF Ratio
--1.88-3.90---
EV/Sales Ratio
3.12-0.271.95---
EV/EBITDA Ratio
-0.09-0.59---
EV/EBIT Ratio
-0.09-0.58---
EV/FCF Ratio
-0.10-1.06---
Debt / Equity Ratio
0.220.210.280.280.110.08
Debt / EBITDA Ratio
-0.51-0.53-0.56-0.68-0.53-0.39
Debt / FCF Ratio
--0.60-1.01-0.78-0.49-0.34
Net Debt / Equity Ratio
-0.76-0.73-0.83-0.65-0.68-1.24
Net Debt / EBITDA Ratio
1.551.671.521.483.305.93
Net Debt / FCF Ratio
-1.902.741.703.025.14
Asset Turnover
0.100.100.100.070.100.13
Quick Ratio
8.757.605.496.236.158.58
Current Ratio
9.007.815.716.466.368.69
Return on Equity (ROE)
-21.40%-44.38%-48.70%-37.76%-25.03%-33.95%
Return on Assets (ROA)
-33.29%-32.52%-34.21%-27.63%-18.11%-23.10%
Return on Invested Capital (ROIC)
-127.97%-127.76%-142.39%-82.74%-85.28%-414.46%
Return on Capital Employed (ROCE)
-36.49%-36.55%-39.29%-30.78%-20.23%-27.42%
Earnings Yield
-30.06%-66.49%-42.22%-44.41%-5.65%-17.60%
FCF Yield
-28.43%-53.65%-25.70%---
Buyback Yield / Dilution
-19.49%-19.49%-41.98%-6.12%-304.93%-728.79%
Total Shareholder Return
-19.49%-19.49%-41.98%-6.12%-304.93%-728.79%
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q